Parsons said the study results "pretty much close the chapter of tenecteplase versus alteplase in the early treatment window for thrombolysis in ischemic stroke (within 4.5 h of symptom onset).

Intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer activity than alteplase, ...

The older the patient, the worse the functional outcome tended to be after endovascular thrombectomy (EVT) for an acute ischemic stroke with a large infarct, observational data suggested. Based on ...

PHOENIX -- Endovascular thrombectomy for large-core acute ischemic stroke improved long-term outcomes, the SELECT2 trial affirmed. The intervention shifted the 1-year modified Rankin Scale (mRS ...

“The best outcomes, explains Dr. Modak, “occur when the medication is administered within 3 to 4.5 hours of the onset of ...

Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset in patients not eligible for endovascular thrombectomy, according to research ...

The session focused on the evolution of stroke care, particularly ischemic strokes, which make up 87% of all strokes. It ...

Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies. The ENIS-3 trial has achieved >33% of target ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...